Discover @ Loyola University Chicago Health Sciences Division - Game Changer: Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD).

Game Changer: Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD). Journal Article

Local Library Link: Find It @ Loyola

Author:	Lake, E
Article Title:	Game Changer: Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD).
Abstract:	No abstract available
Journal Title:	Journal of the American Academy of Dermatology
ISSN:	1097-6787; 0190-9622
Publisher:	Unknown
Date Published:	2018

LUC Authors